Literature DB >> 16273798

The assessment of disease activity and outcomes in psoriatic arthritis.

A Kavanaugh1, S Cassell.   

Abstract

Psoriatic Arthritis (PsA) is a common condition that significantly impacts affected patients. The introduction of novel therapeutic agents for PsA has generated considerable interest in both clinical trials and in clinical care. Thus, there is a great need for standardized outcome measures to assess the activity of disease and the response to therapy. Because psoriasis is a heterogeneous and multi-faceted condition, defining outcome measures has been a challenge. To date, such measures have largely been adapted from related diseases, as described in this essay. Further research is needed to further develop outcome measures for PsA to facilitate optimal treatment of patients with PsA.

Entities:  

Mesh:

Year:  2005        PMID: 16273798

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  The spectrum of psoriatic arthritis in a South African cohort.

Authors:  Jean-Paul Muzemb Kanyik; Annibale Coi; Asgar Ali Kalla
Journal:  Clin Rheumatol       Date:  2017-09-15       Impact factor: 2.980

Review 2.  [Outcome parameters for use in psoriatic arthritis].

Authors:  J Braun; S Wassenberg
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

3.  Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Ilaria Ruffilli; Giusy Elia; Mario Miccoli; Andrea Delle Sedie; Lucrezia Riente; Alessandro Antonelli
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

4.  Extra-articular manifestations in psoriatic arthritis patients.

Authors:  Rosario Peluso; Salvatore Iervolino; Maria Vitiello; Vincenzo Bruner; Gelsy Lupoli; Matteo Nicola Dario Di Minno
Journal:  Clin Rheumatol       Date:  2014-05-08       Impact factor: 2.980

5.  Remission criteria and activity indices in psoriatic arthritis.

Authors:  M L Acosta Felquer; L Ferreyra Garrott; J Marin; E Catay; M Scolnik; V Scaglioni; S Ruta; J Rosa; E R Soriano
Journal:  Clin Rheumatol       Date:  2014-05-13       Impact factor: 2.980

6.  Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis.

Authors:  Mohieldin M Ahmed; Gehan Gamal Elolemy; Aziz K Alfeeli; Ayyoub B Baqer; Adela M Gad
Journal:  Open Access Maced J Med Sci       Date:  2017-08-11

7.  Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.

Authors:  Daniel E Furst; Melody Tran; Emma Sullivan; James Pike; James Piercy; Vivian Herrera; Jacqueline B Palmer
Journal:  Clin Rheumatol       Date:  2017-02-25       Impact factor: 2.980

8.  4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

Authors:  Désirée van der Heijde; Atul Deodhar; Oliver FitzGerald; Roy Fleischmann; Dafna Gladman; Alice B Gottlieb; Bengt Hoepken; Lars Bauer; Oscar Irvin-Sellers; Majed Khraishi; Luke Peterson; Anthony Turkiewicz; Jürgen Wollenhaupt; Philip J Mease
Journal:  RMD Open       Date:  2018-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.